Preclinical testing of CLB073 has identified the compound as having anti-Mtb activity. The compound is owned by Calibr and has been exclusively licesenced to Bill and Melinda Gates Medical Research Institute (GMRI). The compound was developed by David Russell and Brian VanderVen at Cornell University's College of Vetinary Medicine.
CLB073 is active on adenyl cyclase (Rv1625c), which is involved in Mtb's ability to metabolize cholesterol. Cholesterol metabolism has recently been determined by experts to be an important new drug target.
In preclinical mouse studies, CLB073 significantly enhanced the efficacy of Nix-TB drug regimen, the current standard of care for drug-resistant tuberculosis.